|Treatment Options in Relapsed/Refractory Multiple Myeloma: Caring for the Patient During the First Relapse and Beyond|
Sagar Lonial, MD, FACP
|Release Date: August 22, 2018|
Expiration Date: August 22, 2019
While evolving pharmacologic options continue to improve the management of relapsed/refractory multiple myeloma (RRMM), the selection of therapy following a first relapse and beyond is critical for improving prognoses and outcomes. This activity will address the efficacy and safety of current and emerging therapies for RRMM as well as strategies for overcoming challenges that clinicians often encounter when integrating novel agents into practice.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
|Begin, Earn CreditView Only, No Credit|